Search

Your search keyword '"Abbou, Samuel"' showing total 165 results

Search Constraints

Start Over You searched for: Author "Abbou, Samuel" Remove constraint Author: "Abbou, Samuel"
165 results on '"Abbou, Samuel"'

Search Results

1. Supra-tentorial Ependymomas with ZFTA Fusion, YAP1 Fusion, and Astroblastomas, MN1-altered: Characteristic Imaging Features

2. CNS erythroblastic sarcoma: a potential emerging pediatric tumor type characterized by NFIA::RUNX1T1/3 fusions

3. Imaging features to distinguish posterior fossa ependymoma subgroups

4. AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial

7. Sequential analysis of cfDNA reveals clonal evolution in neuroblastoma patients receiving ALK targeted therapy

8. Medulloblastomas with ELP1 pathogenic variants: a weakly penetrant syndrome with a restricted spectrum in a limited age window

9. Long-Term Weight Gain in Children with Craniopharyngioma

10. Supplementary Table S4 from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

11. Data from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

12. Supplementary Figure S1 from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

13. Medulloblastomas with ELP1 pathogenic variants: A weakly penetrant syndrome with a restricted spectrum in a limited age window

15. Laser interstitial thermal therapy is effective and safe for the treatment of brain tumors in NF1 patients after cerebral revascularization for moyamoya angiopathy: a report on two cases

16. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

17. EPID-10. CNSONTRK STUDY: CLINICAL CHARACTERISTICS AND OUTCOME OF CENTRAL NERVOUS SYSTEM TUMORS HARBORING NTRK GENE FUSIONS

18. Neurofibromatosis type 1 mosaicism in patients with constitutional mismatch repair deficiency

19. Imaging features to distinguish posterior fossa ependymoma subgroups

20. Neurofibromatosis type 1 mosaicism in patients with constitutional mismatch repair deficiency.

21. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study

22. Dispensing Oral Temozolomide in Children: Precision and Stability of a Novel and Ready to Use Liquid Formulation in Comparison with Capsule Derived Mixtures.

23. Abstract CT087: Phase I/II study of the WEE1 inhibitor adavosertib in combination with carboplatin in children with advanced malignancies: arm C of the AcSé-ESMART trial

24. Data from The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

25. Supplementary Data from The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

26. Supplementary methods: from Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial

27. Supplementary table 2. from Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial

28. Supplementary table 1. from Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial

29. Assessment of Puberty and Hypothalamic–Pituitary–Gonadal Axis Function After Childhood Brain Tumor Treatment

30. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

31. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

32. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

34. HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.

35. HGG-40. NF1 mosaicism in a CMMRD-patient with a glioblastoma

36. Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement

38. Development of a Hospital Compounded, Taste-Masked, Temozolomide Oral Suspension and 5-Year Real-Life Experience in Treating Paediatric Patients

39. Decision-tree derivation and external validation of a new clinical decision rule (DISCERN-FN) to predict the risk of severe infection during febrile neutropenia in children treated for cancer

40. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

41. High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort

43. Additional file 16 of Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions

44. Additional file 8 of Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions

45. Additional file 7 of Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions

46. Additional file 6 of Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions

47. Additional file 5 of Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions

48. Pineal alveolar rhabdomyosarcoma with PAX3:NCOA2 fusion inducing OLIG2 expression, a potential pitfall in the central nervous system

49. High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort.

50. Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma

Catalog

Books, media, physical & digital resources